Literature DB >> 27350077

Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.

Maria Komisarenko1, Narhari Timilshina1, Patrick O Richard1, Shabbir M H Alibhai2, Robert Hamilton1, Girish Kulkarni1, Alexandre Zlotta1, Neil Fleshner1, Antonio Finelli3.   

Abstract

PURPOSE: We reviewed various existing active surveillance criteria and determined the competing trade-offs of the stricter vs more inclusive active surveillance criteria.
MATERIALS AND METHODS: Men enrolled in an active surveillance program at Princess Margaret Cancer Centre between 1998 and 2014 were identified through a prospectively maintained database. All patients were assessed for entry eligibility into the Prostate Cancer Research International: Active Surveillance, Johns Hopkins, University of Miami, University of California San Francisco, Memorial Sloan Kettering Cancer Center, University of Toronto-Sunnybrook and Royal Marsden protocols. The 2-sided t-test, ANOVA, Wilcoxon rank sum or chi-square tests were used for comparison as appropriate.
RESULTS: Of the 1,365 men identified 1,085 met the Princess Margaret Cancer Centre inclusion criteria. When the Johns Hopkins, Prostate Cancer Research International: Active Surveillance and University of Miami criteria were applied 15.2%, 11.5% and 11.3% of these patients were excluded from active surveillance, respectively. No significant differences were noted between men who met the Princess Margaret Cancer Centre criteria and those who were excluded based on more stringent criteria when grade or volume reclassification was compared. No significant differences in prostate specific antigen velocity or the number of patients who proceeded to seek treatment were noted (p >0.1). Rates of biochemical recurrence among patients who chose to undergo radical prostatectomy after initial active surveillance were not different between men who met the more inclusive vs more exclusive active surveillance protocols.
CONCLUSIONS: More selective criteria do not significantly improve short-term outcomes when considering the relative risk of grade reclassification or biochemical failure after treatment. In an era of increased awareness regarding the over diagnosis and overtreatment of prostate cancer, we believe that stricter entry criteria should be reconsidered.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  eligibility determination; prostatic neoplasms; watchful waiting

Mesh:

Year:  2016        PMID: 27350077     DOI: 10.1016/j.juro.2016.06.083

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  The american urological association's prostate cancer screening guideline: Which cancers will be missed in average-risk men aged 40 to 54 years?

Authors:  Thomas E Moody; Curtis L Spraitzar; Elizabeth Eisenhart; Scott Tully
Journal:  Rev Urol       Date:  2017

Review 2.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

3.  A novel predictor of clinical progression in patients on active surveillance for prostate cancer.

Authors:  Guan Hee Tan; Antonio Finelli; Ardalan Ahmad; Marian S Wettstein; Thenappan Chandrasekar; Alexandre R Zlotta; Neil E Fleshner; Robert J Hamilton; Girish S Kulkarni; Khaled Ajib; Gregory Nason; Nathan Perlis
Journal:  Can Urol Assoc J       Date:  2019-08-31       Impact factor: 1.862

4.  Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?

Authors:  Saleh Ghiasy; Amir Reza Abedi; Afshin Moradi; Seyed Yousef Hosseini; Morteza Fallah Karkan; Ghazal Sadri; Mohammadreza Davari
Journal:  Turk J Urol       Date:  2018-11-19

5.  Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.

Authors:  François Audenet; Emily A Vertosick; Samson W Fine; Daniel D Sjoberg; Andrew J Vickers; Victor E Reuter; James A Eastham; Peter T Scardino; Karim A Touijer
Journal:  J Urol       Date:  2017-10-10       Impact factor: 7.450

Review 6.  Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes.

Authors:  Maria Komisarenko; Lisa J Martin; Antonio Finelli
Journal:  Transl Androl Urol       Date:  2018-04

7.  Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years.

Authors:  Brayden March; George Koufogiannis; Mark Louie-Johnsun
Journal:  Prostate Int       Date:  2017-04-07

8.  Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer-A population-based cohort study.

Authors:  Rano Matta; Amanda E Hird; Erind Dvorani; Refik Saskin; Gregory J Nason; Girish Kulkarni; Ronald T Kodama; Sender Herschorn; Robert K Nam
Journal:  Cancer Med       Date:  2020-08-05       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.